Altimmune

US · ALT #3727 by market cap

2.66 -0.01 -0.37%

Live - 5344 symbols - heartbeat 40s ago · 2026-10-08 09:11

Pre-market 2.69 +1.13%

After-hours 2.67 +0.38%

Overnight 2.68 +0.75%

Market cap: 517.42M
P/E (TTM): -3.50
P/B: 1.09
EPS: -1.00
Div yield: 0.00%
52W pos: 3%

Reader sentiment Are you bullish or bearish on ALT?

Anonymous reader poll. Unscientific, not investment advice.

About Altimmune

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. Its lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Founded: 1997
CEO: Mr. Jerome B. Durso
Employees: 57
Headquarters: Gaithersburg, Maryland, United States of America
Fiscal year end: 12-31
Website: altimmune.com

Company profile

Exchange: US
Symbol: ALT
Market-cap rank: #3727
Market cap: 517.42M
Float cap: 437.24M
Shares out: 194.52M
Float shares: 164.37M

Sectors & themes

Weight Loss Drugs Biotechnology

Browse all sectors & themes

Quote time 2026-10-08 09:11:30 · For reference only, not investment advice and not tailored to your situation.